Background: Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death. Sorafenib, a multitarget angiogenesis inhibitor, is an approved frontline treatment for advanced HCC in Western countries, although a complete response (CR) to treatment is infrequently reported. Capecitabine, an oral fluoropyrimidine, has been shown to be effect in both treatment-naïve patients and those previously treated with sorafenib. To date, however, only one case of sustained CR to metronomic capecitabine has been reported. Case presentation: We describe three cases of advanced HCC treated with metronomic capecitabine where a CR was obtained. In the first case, capecitabine was administered as first line therapy; in the second case, capecitabine was used after intolerance to sorafenib; while in the third case, capecitabine was administered after sorafenib failure. Conclusion: Capecitabine is a potentially important treatment option for patients with advanced HCC and may even represent a cure in certain cases.
CITATION STYLE
Brandi, G., Venturi, M., De Lorenzo, S., Garuti, F., Frega, G., Palloni, A., … Barbera, M. A. (2018). Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: A report of three cases. Cancer Communications, 38(1). https://doi.org/10.1186/s40880-018-0312-1
Mendeley helps you to discover research relevant for your work.